ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: () Report Updated: Sep 29, 2014 | Print This Page

Get more stock ratings by Louis Navellier

(AFFY)

Rating: Volatility:
Total Grade: Industry:
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions in the United States. It offers OMONTYS (peginesatide) Injection for the treatment of anemia in chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. The company has strategic alliance agreement with Takeda Pharmaceutical Company Limited to develop and commercialize OMONTYS. Affymax, Inc. was founded in 2001 and is headquartered in Palo Alto, California.

Recent News: